Compound Summary
Esatenolol
Compound Information
Esatenolol
Compound Name: | Esatenolol |
Compound CID: | 175540 |
Synonyms: | Esatenolol (S)-(-)-Atenolol (S)-Atenolol 93379-54-5 S-Atenolol More... |
Iupac Name: | 2-[4-[(2S)-2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide |
InChI: | InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)/t12-/m0/s1 |
InChIKey: | METKIMKYRPQLGS-LBPRGKRZSA-N |
Canonical Smiles: | CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O |
Isomeric Smiles: | CC(C)NC[C@@H](COC1=CC=C(C=C1)CC(=O)N)O |
Molecular Weight: | 266.34 |
Molecular Formula: | C14H22N2O3 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
Esatenolol
Molecular Weight: | 266.34 |
Molecular Formula: | C14H22N2O3 |
Hydrogen Bond Donor Count: | 3 |
Hydrogen Bond Acceptor Count: | 4 |
Rotatable Bond Count: | 8 |
Heavy Atom Count: | 19 |
Complexity: | 263 |
Synonyms
Esatenolol
| Esatenolol | Esatenolol |
|---|---|
Esatenolol |
(S)-(-)-Atenolol |
(S)-Atenolol |
93379-54-5 |
S-Atenolol |
(-)-Atenolol |
S(-)-Atenolol |
UNII-DPF757BOSR |
S-(-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide |
2-(p-((2S)-2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide |
(S)-4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide |
DPF757BOSR |
CHEBI:31556 |
2-4-(2S)-2-hydroxy-3-(propan-2-ylamino)propoxyphenylacetamide |
MFCD00074918 |
Esatenolol INN |
S-(-)-Atenolol |
2-4-({(2S)2-hydroxy-3-(propan-2-yl)aminopropyl}oxy)phenylacetamide |
SR-01000597666 |
NCGC00093636-03 |
atenolol-(-) |
CAS-56715-13-0 |
(S)(-)-atenolol |
(S)-()-Atenolol |
Tocris-0387 |
Tocris-0393 |
Esatenolol (JAN/INN) |
Lopac-A-142 |
Lopac-A-143 |
Prestwick0_000536 |
Prestwick1_000536 |
Prestwick2_000536 |
Prestwick3_000953 |
Lopac-A-7655 |
Benzeneacetamide, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, (S)- |
SCHEMBL4363 |
Lopac0_000156 |
BSPBio_000946 |
MLS002153864 |
(S)-(-)-Atenolol, powder |
SPBio_002472 |
(S)-(-)-Atenolol 99% |
BPBio1_001042 |
CHEMBL343633 |
(S)-(-)-Atenolol, 99% |
DTXSID10239405 |
HMS2097P08 |
HMS2235B16 |
HMS3260O14 |
HMS3266K19 |
HMS3411I05 |
HMS3675I05 |
HMS3714P08 |
ZINC113415 |
Tox21_500156 |
(-)-4-2-Hydroxy-3-(1-methylethyl)aminopropoxybenzeneacetamide |
GEO-02804 |
AKOS015894675 |
CCG-204251 |
DB13443 |
LP00156 |
SDCCGSBI-0050144.P002 |
NCGC00015007-01 |
NCGC00015007-02 |
NCGC00015007-03 |
NCGC00015007-04 |
NCGC00015007-05 |
NCGC00015007-12 |
NCGC00016880-01 |
NCGC00016880-02 |
NCGC00016880-03 |
NCGC00016880-04 |
NCGC00016880-05 |
NCGC00016880-06 |
NCGC00016880-07 |
NCGC00016880-13 |
NCGC00024566-01 |
NCGC00024570-01 |
NCGC00024570-02 |
NCGC00024570-03 |
NCGC00024570-04 |
NCGC00093636-01 |
NCGC00093636-02 |
NCGC00260841-01 |
SMR000326748 |
CAS-93379-54-5 |
A-143 |
AB00513856 |
B6289 |
EU-0100156 |
V1672 |
A13427 |
D01471 |
SR-01000597666-1 |
SR-01000597666-3 |
W-200527 |
BRD-K44993696-001-03-2 |
BRD-K44993696-001-05-7 |
Q24255323 |
UNII-50VV3VW0TI component METKIMKYRPQLGS-LBPRGKRZSA-N |
(S)-2-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide |
(S)-(-)-4-2-Hydroxy-3-(1-methylethyl)aminopropoxybenzeneacetamide |
Experimental Data
Esatenolol
| Species | Dose | Unit | Control(Avg days) | Treatment(Avg days) | Avg/Med Lifespan Change(%) | Control(Max days) | Treatment(Max days) | Max Lifespan Change(%) | Significant | Strain | Gender | PubMed | Avg/Med Lifespan Change tab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33.000000000000000 | umol/L | -2.000000000000000 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
Esatenolol
Statistics Data
Esatenolol
| Species | Avg/Med Lifespan Change(%) | Max Lifespan Change(%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | -2.000000000000000 | 1 | 1 |
Statistics Data Visualization
Esatenolol
